Peer-reviewed veterinary case report
Rivaroxaban treatment and blood clot monitoring in two dogs
By Uchida, Mona et al.·Published in The Journal of veterinary medical science·2020·Department of Veterinary Clinical Pathobiology, Japan·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Treatment with rivaroxaban and monitoring of coagulation profiles in two dogs with venous thromboembolism.
- Species:
- dog
Plain-English summary
Two dogs with immune-mediated hemolytic anemia (a condition where the immune system attacks red blood cells) developed blood clots that caused fluid buildup in their bellies. Initially, they were treated with medications to suppress their immune response and prevent clotting, but they still had complications. After starting a new medication called rivaroxaban, the fluid in their bellies decreased, and their blood tests showed improvement. However, one dog experienced some bleeding issues as a side effect. Overall, rivaroxaban helped manage the blood clots effectively.
People also search for: dog blood clots treatment · immune-mediated hemolytic anemia in dogs · rivaroxaban for dogs · dog bleeding after medication
Abstract
Two dogs with immune-mediated hemolytic anemia complicated with thromboembolism were presented. Both of the dogs were initially treated with immunosuppressive therapy in conjunction with dalteparin and clopidogrel. Although the immunosuppressive therapy was effective, peritoneal effusion due to thromboembolism was observed during the course of the disease in these dogs. After initiation of rivaroxaban treatment, peritoneal effusion decreased immediately in parallel with the normalization of D-dimer, antithrombin (AT), and thrombin-antithrombin complex (TAT). Hematochezia, cutaneous hemorrhage, and hematuria were observed as adverse events after administration of rivaroxaban in one case. Rivaroxaban was effective for the control of thromboembolism secondary to immune-mediated hemolytic anemia, and D-dimer, AT, and TAT were useful to monitor the status of thromboembolic disease in dogs.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/32655095/